Kiniksa Pharmaceuticals International (KNSA) Receivables - Other (2022)

Kiniksa Pharmaceuticals International (KNSA) posted Receivables - Other of $7.7 million for Q4 2022.

Kiniksa Pharmaceuticals International (KNSA) Receivables - Other (2022) Analysis & Trends

Kiniksa Pharmaceuticals International's Receivables - Other history runs 1 years deep, the most recent figure standing at $7.7 million for Q4 2022.

  • Quarterly Receivables - Other changed N/A year-over-year to $7.7 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $7.7 million (changed N/A YoY) and the FY2022 annual result came in at $7.7 million, changed N/A from the prior year.
  • Receivables - Other was $7.7 million for Q4 2022 at Kiniksa Pharmaceuticals International.
  • Across five years, Receivables - Other topped out at $7.7 million in Q4 2022 and bottomed at $7.7 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Kiniksa Pharmaceuticals International 4.82 Bn 4.36 Bn 193.47 Mn

Historic Data

Download Data
DateValue
Dec 31, 2022 7.66 Mn
Dec 31, 2022 7.66 Mn